NEW YORK (GenomeWeb) – Fluidigm announced after the close of the markets on Wednesday that it will suspend its full-year 2016 revenue guidance based on its assessment of third quarter revenues.

According to management's preliminary analysis, the firm said, revenues for the three months ended Sept. 30 fell approximately 23 percent year over year, to $22.2 million from $28.6 million. Wall Street analysts had expected revenues of $29.3 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.